Redesign Science

Founded in 2017, Redesign Science is a platform biotech working at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery. We deploy our platform technology to develop first-in-class Protein Interaction Modulators against validated targets known to drive progression of multiple oncogenic and inflammatory diseases.[1][2]

Visit website Suggest an update

2017 Founded1 Person on the graph

Overview

Redesign Science is a biotechnology company listed in the New York City AI sector [1]. Founded in 2017, the company operates as a platform biotech at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery [2]. Redesign Science deploys its platform technology to develop Protein Interaction Modulators targeting validated targets associated with oncogenic and inflammatory diseases [2]. According to LinkedIn, the company operates in the biotechnology research industry [3].

Business address: 180 Varick St, New York, New York, 10014. [6]

Growth & traction

LinkedIn lists 5 people working at Redesign Science. [4]

Key people

David RooklinCofounder, President

Alumni

Something wrong or missing? Send an update. Fixed within 24 hours.